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RESULTS

OBJECTIVE
• To investigate the efficacy, safety and usage patterns of pushdose phenylephrine in non-operative, critically ill patients.

RESULTS

• 143 patients were analyzed and twelve received ≥ 1 dose,
resulting in a total of 158 administrations of push-dose
phenylephrine

• Adverse drug reactions occurred within 30 minutes in 11 (7.7%)
patients
Figure 5: Adverse Drug Reactions

Figure 1: Demographics

BACKGROUND

Gender (male)

• In the last five years, there has been an increase in literature
evaluating the use of push-dose vasopressors in
hemodynamically unstable patients within emergency
departments or critical care areas.1-3
• The most common indications include hypotension in the periintubation period, during procedural events, and nonprocedure related episodes.
• In May 2017, push-dose phenylephrine, packaged as 1000
mcg/10 mL syringes, was approved for use in the emergency
department at Parkview Regional Medical Center. In July
2019, this was expanded for use in critical care areas.
• Push-dose phenylephrine has been associated with adverse
drug reactions, such as hypertension, bradycardia, and
extravasation.1-4

Per-intubation

n= 73 (46%)

Non-procedural

n= 70 (44%)

Other procedural

n= 15 (10%)

METHODS
• Retrospective review of all patients outside of the OR who
received at least one push-dose of phenylephrine during an
inpatient stay between June 2018- May 2020.
• The impact of phenylephrine on hemodynamic parameters was
evaluated by comparing mean arterial pressure (MAP) and
heart rate (HR) within 30 minutes pre and post drug
administration.
• The effectiveness of phenylephrine was evaluated by
evaluating how many patients required additional interventions
to increase blood pressure (e.g. intravenous fluid bolus,
continuous infusion vasopressor)
• Adverse drug reactions (ADRs) resulting from push-dose
phenylephrine and interventions to mitigate these were
collected.
• An ADR was defined as systolic blood pressure (SBP) >180
mmHg, diastolic blood pressure (DBP) >100 mmHg, heart rate
(HR) < 50 beats per minute (bpm), and/or extravasation that
occurred within 30 minutes of the dose.

6

n= 90 (63%)

5
Patients

Indication for administration

Department of administration
Medical ICU
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Other

n= 18 (11%)
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• Interventions in patients with bradycardia (HR <50) included
atropine (n=2) and isoproterenol (n=1)
• No interventions were administered to patients who developed
hypertension

• Median dose of phenylephrine was 200mcg (IQR:100-300)
Figure 2: Phenylephrine doses
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Patients
• Additional therapies to increase blood pressure were used within
one hour of phenylephrine administration in 74 patients
• 8 of these patients received >1 additional therapy
Figure 3: Additional interventions
Vasopressor infusion

n= 69 (48%)

IV fluid (dextrose of NS) bolus

n= 9 (6%)

Albumin bolus

n= 4 (3%)

Figure 4: Average MAP after Phenylephrine
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• Phenylephrine was most often utilized in the peri-intubation
setting within the medical ICU
• The median dose of phenylephrine administered was 200 mcg
• Push-dose phenylephrine proved to be relatively well-tolerated,
and ADRs occurred in 11 patients
• The efficacy of push-dose phenylephrine proved to be transient,
and many patients required additional therapies within one hour
of the dose to raise blood pressure
• The utilization of push-dose phenylephrine in critical care patients
does not negate the need for additional vasopressor support in
the majority of patients
• Further research is warranted to assess the duration of action
and prevention of invasive interventions
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